Answer
In the Phase III single-agent study, subcutaneous Velcade (bortezomib) caused local reactions in 6% of patients, mostly redness, resolving in a median of 6 days; two patients needed dose modification, and two (1%) had severe reactions—one pruritus and one redness.
Sources for this answer
- Velcade 3.5mg powder for solution for injection (Great Britain)Janssen-Cilag Ltd (a Johnson & Johnson Company) · emc · SmPC §4.8 Undesirable effects · Version 37Document updated
Sources checked